A whey/guar “preload” improves postprandial glycaemia and glycated haemoglobin levels in type 2 diabetes: A 12‐week, single‐blind, randomized, placebo‐controlled trial
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Aims: To evaluate the effects of 12 weeks of treatment with a whey/guar preload on gastric emptying, postprandial glycaemia and glycated haemoglobin (HbA1c) levels in people with type 2 diabetes (T2DM). Materials and methods: A total of 79 people with T2DM, managed on diet or metformin (HbA1c 49 ± 0.7 mmol/mol [6.6 ± 0.1%]), were randomized, in single‐blind fashion, to receive 150 mL flavoured preloads, containing either 17 g whey protein plus 5 g guar (n = 37) or flavoured placebo (n = 42), 15 minutes before two meals, each day for 12 weeks. Blood glucose and gastric emptying (breath test) were measured before and after a mashed potato meal at baseline (without preload), and after the preload at the beginning (week 1) and end (week 12) of treatment. HbA1c levels, energy intake, weight and body composition were also evaluated. Results: Gastric emptying was slower ( P < 0.01) and postprandial blood glucose levels lower ( P < 0.05) with the whey/guar preload compared to placebo preload, and the magnitude of reduction in glycaemia was related to the rate of gastric emptying at both week 1 (r = −0.54, P < 0.001) and week 12 (r = −0.54, P < 0.0001). At the end of treatment, there was a 1 mmol/mol [0.1%] reduction in HbA1c in the whey/guar group compared to the placebo group (49 ± 1.0 mmol/mol [6.6 ± 0.05%] vs. 50 ± 0.8 mmol/mol [6.7 ± 0.05%]; P < 0.05). There were no differences in energy intake, body weight, or lean or fat mass between the groups. Conclusions: In patients with well‐controlled T2DM, 12 weeks' treatment with a low‐dose whey/guar preload, taken twice daily before meals, had sustained effects of slowing gastric emptying and reducing postprandial blood glucose, which were associated with a modest reduction in HbA1c, without causing weight gain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461 · cited 2×
“However, approaches such as this that specifically target postprandial glycaemia are less likely to be effective in people with poor glycaemic control (HbA1c ≥ 9%), in whom fasting blood glucose makes the predominant contribution to HbA1c levels.(2) Given that slowing of gastric emptying appeared to be the predominant…”
BackgroundPlasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857 · cited 1×
“The incretin hormones GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) are known to be stimulated by whey protein and account for the “incretin effect”, the phenomenon by which insulin secretion is augmented when glucose is given enterally when compared to an isoglycaemic intravenous glucose infusion.(36)…”
BackgroundRelationship between oral glucose tolerance and gastric emptying in normal healthy subjects
Horowitz, M., Edelbroek, M. A. L., Wishart, J. M., & Straathof, J. W. (1993) · Diabetologia · doi:10.1007/bf00400362 · Cited by 469
Self-citationNilsson, M., Holst, J. J., & Björck, I. M. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.4.996 · Cited by 374
Parker, B. A., Sturm, K., MacIntosh, C. G., Feinle, C., Horowitz, M., & Chapman, I. M. (2004) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1601768 · Cited by 322 · cited 2×
“Symptoms of hunger, desire to eat, projected food consumption, and fullness were assessed before and after the test meal using a validated 100-mm VAS.22”
MethodSelf-citationCalbet, J. A. L., & MacLean, D. A. (2002) · The Journal of Nutrition · doi:10.1093/jn/132.8.2174 · Cited by 253
Riddle, M., Umpierrez, G., DiGenio, A., Zhou, R., & Rosenstock, J. (2011) · Diabetes Care · doi:10.2337/dc11-0632 · Cited by 219
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1935 · Cited by 218
Postprandial Hyperglycemia and Glycemic Variability
Standl, E., Schnell, O., & Ceriello, A. (2011) · Diabetes Care · doi:10.2337/dc11-s206 · Cited by 183
Cited by
Papakonstantinou, E., Oikonomou, C., Nychas, G., & Dimitriadis, G. D. (2022) · Nutrients · doi:10.3390/nu14040823 · Cited by 199
Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae719 · Cited by 157
“Gastric emptying may be markedly delayed in the absence of symptoms, and in some individuals with severe symptoms, gastric emptying may be normal or accelerated (11).”
Self-citationJalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., Umapathysivam, M. M., Wu, T., Quast, D. R., Plummer, M. P., Nauck, M. A., & Horowitz, M. (2024) · Endocrinology · doi:10.1210/endocr/bqae155 · Cited by 61
Self-citationNesti, L., Mengozzi, A., & Tricò, D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00144 · Cited by 53
Amirani, E., Milajerdi, A., Reiner, Ž., Mirzaei, H., Mansournia, M. A., & Asemi, Z. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01384-7 · Cited by 47
Smedegaard, S., Kampmann, U., Ovesen, P. G., Støvring, H., & Rittig, N. (2023) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.05.012 · Cited by 28
Chiang, S.-W., Liu, H.-W., Loh, E.-W., Tam, K.-W., Wang, J.-Y., Huang, W.-L., & Kuan, Y.-C. (2022) · Nutrition Research · doi:10.1016/j.nutres.2022.04.002 · Cited by 28
Giglio, B. M., Lobo, P. C. B., & Pimentel, G. D. (2023) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.09.014 · Cited by 18
Metadata
- Authors
- Watson, L. E., Phillips, L. K., Wu, T., Bound, M. J., Checklin, H. L., Grivell, J., Jones, K. L., Clifton, P. M., Horowitz, M., & Rayner, C. K.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2019-01-04
- Volume
- 21
- Issue
- 4
- Pages
- 930-938
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2908165731
- Cited by
- 58
- References
- 12
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.